OSE Immunotherapeutics – Key opinion leader webinar


OSE Immunotherapeutics – Key opinion leader webinar









Join OSE Immunotherapeutics in its lung cancer-focused key opinion leader investor webinar.

The event will feature Dr Stephen Liu, medical oncologist, Georgetown University (Washington DC, United States), who will discuss the unmet medical need and therapeutic landscape in lung cancer.

Professor Benjamin Besse, medical oncologist, director of clinical research at the Gustave Roussy Institute (Villejuif, France), will present the Artemia study, the registration Phase III clinical trial of Tedopi® in non-small cell lung cancer.

Soo Romanoff, managing director of healthcare at Edison Group, will chair the panel and Q&A.

Event details

Date: 7 June 2024

Time: 6pm (CET)/12pm (ET)/5pm (BST)

Register here

About OSE Immunotherapeutics

OSE Immunotherapeutics (PAR: OSE) is a leading biotech company committed to pioneering breakthroughs in immuno-oncology and immuno-inflammation. At the forefront of its portfolio is Tedopi®, a revolutionary cancer vaccine that has recently demonstrated promising outcomes in a Phase III study involving non-small cell lung cancer patients facing secondary resistance following checkpoint inhibitor treatment. The company’s R&D pipeline is robust and diverse, ensuring that its progress remains resilient and independent of any singular subsector.

For more information on OSE Immunotherapeutics, please read the latest updates on Edison’s website and visit the company’s website.

Register your interest
Please enable JavaScript in your browser to complete this form.
Investor type

We will only use your personal information to provide the services and products that you have signed up for. You will receive a confirmation email after subscribing and can tailor your preferences or unsubscribe at any time by using the links provided. Edison Group's Privacy Policy and Terms & Conditions can be found here.


Related Research

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free